398 related articles for article (PubMed ID: 33671049)
1. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Kotyla PJ; Engelmann M; Giemza-Stokłosa J; Wnuk B; Islam MA
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671049
[TBL] [Abstract][Full Text] [Related]
2. Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk.
Rajasimhan S; Pamuk O; Katz JD
Drugs Aging; 2020 Aug; 37(8):551-558. PubMed ID: 32514874
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC; Hider SL; Scott DL
Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
[TBL] [Abstract][Full Text] [Related]
6. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Kotyla PJ; Islam MA; Engelmann M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
[TBL] [Abstract][Full Text] [Related]
7. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
8. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Zak M; Dengler HS; Rajapaksa NS
Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
[TBL] [Abstract][Full Text] [Related]
9. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitors for asthma.
Georas SN; Donohue P; Connolly M; Wechsler ME
J Allergy Clin Immunol; 2021 Oct; 148(4):953-963. PubMed ID: 34625142
[TBL] [Abstract][Full Text] [Related]
12. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
14. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
16. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Atzeni F; Popa CD; Nucera V; Nurmohamed MT
Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
[TBL] [Abstract][Full Text] [Related]
17. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
18. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
20. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
Kim HO
Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
